-
Connoya IL-4Rα mAb Phase II clinical success
Time of Update: 2022-05-26
Article source: Medical Cube InfoAuthor: sunshineOn March 30, Connoya announced that its Class 1 new drug CM310 has achieved all efficacy endpoints and obtained positive results in its Phase II clinical study (CM310NP001) for chronic rhinosinusitis with nasal polyps .
-
Tengshengbo Pharmaceutical for the Treatment of Chronic Hepatitis B Announces the Latest Results of Phase 2 of RNAi Therapy
Time of Update: 2022-05-26
Updated data from a Phase 2 randomized, double-blind, placebo-controlled trial of nucleic acid (siRNA) BRII-835 (VIR-2218) in Chinese patients with chronic hepatitis B virus (HBV) infection, meeting on March 30 It will be held online in Seoul, South Korea from April 3 to April 3 .
-
Double progression-free survival with PARP inhibitor as first-line maintenance therapy for ovarian cancer
Time of Update: 2022-05-26
References:[1] Clovis Oncology's Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial.
-
Junshi Bio's anti-CD112R monoclonal antibody was approved for clinical use in the United States
Time of Update: 2022-05-26
On April 3, Junshi Bio announced that the company's self-developed anti-CD112R monoclonal antibody injection (project code: TAB009/JS009) has been approved by the US FDA for a clinical trial application for the treatment of advanced solid tumors .
-
A new drug for the treatment of hyperammonemia, Kaglutamic acid dispersible tablets, was declared for listing in China
Time of Update: 2022-05-26
According to public information, this is a rare disease treatment product called Carbaglu, which was initially approved overseas for hyperammonemia caused by N-acetylglutamate synthase (NAGS) deficiency .
The enzyme (NAGS) catalyzes the synthesis and is an important allosteric activator of the essential carbamoyl phosphate synthase-1 (CPS-1) in liver mitochondria .
-
WuXi Ju Norici Orenza Injection Approved for Second-Line Treatment of LBCL
Time of Update: 2022-05-26
On March 31, WuXi Junuo announced that its CD19-targeting autologous chimeric antigen receptor T (CAR-T) cell immunotherapy product, Benoda® (Rigiorenza Injection), is used in the second-line treatment of large The pivotal clinical trial application for B-cell lymphoma has been granted implicit approval by the National Medical Products Administration (NMPA) of China .
-
Liu Lijun Ren Ruizheng Head of Gene Biology Department
Time of Update: 2022-05-26
Lijun Liu will be responsible for the analysis, testing and evaluation of the company's gene editing products in the preclinical and clinical stages, and participate in the project establishment of the products .
-
The world's first!
Time of Update: 2022-05-26
It is a First-in-Class bispecific antibody that simultaneously targets tumor antigen B7H4 and T cell costimulatory molecule 4-1BB .
The unique tumor expression specificity and immunomodulatory activity of HBM7008 is expected to produce better efficacy in PD-L1-negative patients or patients who are resistant to PD-1/PD-L1 immunotherapy drugs .
-
The PCSK9 targeted drug market is about to explode, and the blockbuster product of 1 billion US dollars has appeared
Time of Update: 2022-05-26
Bococizumab, a PCSK9-targeting humanized monoclonal antibody developed by Pfizer, can significantly reduce LDL-C levels and the incidence of cardiovascular events in patients at high risk of cardiovascular events .
-
Read the article to understand how to understand and manage ADC drug resistance
Time of Update: 2022-05-26
Cancers 2022, 14, 154 (the same below)Generally, the mechanism of action of ADC drugs mainly includes the following steps: the antibody in the ADC drug binds to the antigen HER2 expressed on the cell surface, and then the complex formed by ADC-HER2 is internalized through receptor-mediated endocytosis or pinocytosis.
-
FDA Breakthrough Therapy Designation for Pfizer's RSV Vaccine Protects the Elderly
Time of Update: 2022-05-26
Today, Pfizer announced that its investigational respiratory syncytial virus (RSV) vaccine PF-06928316 (also known as RSVpreF) has been granted Breakthrough Therapy Designation by the U.
References:[1] Pfizer Granted FDA Breakthrough Therapy Designation for Respiratory Syncytial Virus Vaccine Candidate for the Prevention of RSV in Older Adults.
-
Pfizer's Oral S1P Modulator for Ulcerative Colitis Meets Primary Endpoint of Phase 3 Clinical Trial
Time of Update: 2022-05-26
Etrasimod is an investigational once-daily oral selective sphingosine 1-phosphate (S1P) receptor modulator being developed for the treatment of moderately to severely active ulcerative colitis (UC) .
References:[1] Pfizer Announces Positive Top-Line Results for Phase 3 Trial of Etrasimod in Ulcerative Colitis Patients.
-
Tengsheng Biopharmaceuticals and Sinopharm reached a cooperation to jointly commercialize the new crown neutralizing antibody
Time of Update: 2022-05-26
On December 8, 2021, the combination therapy of ambavirumab/romisevirumab was approved by the National Medical Products Administration (NMPA) for the treatment of mild and common patients with progression to severe (including hospitalization or death) ) adult and adolescent (12-17 years old, body weight ≥40 kg) patients with novel coronavirus infection (COVID-19) with high risk factors .
-
Hold hands with Lilly!
Time of Update: 2022-05-26
On March 28, Innovent and Eli Lilly jointly announced that the two parties will deepen their strategic cooperation and have reached an agreement on the following matters: 1) Innovent obtains access to
-
Junjing Bio's fourth-generation EGFR inhibitor applied for clinical application
Time of Update: 2022-05-26
At present, domestic companies developing fourth-generation EGFR inhibitors include Betta Pharmaceuticals, Zai Lab, Chia Tai Tianqing, Hongyun Bio, Qilu Pharmaceutical, and Jinan University .
-
Target TROP-2!
Time of Update: 2022-05-26
(hereinafter referred to as "Baikai Pharmaceutical") announced that its Phase 1 clinical trial application (IND) of its innovative antibody-drug conjugate (ADC) BIO-106 targeting TROP-2 has been obtained.
Due to the high expression of TROP-2 in various solid tumors, it has become a new target for researchers to develop antibody-drug conjugates .
-
Public comments on the check points for drug marketing authorization holders
Time of Update: 2022-05-25
Recently, the State Food and Drug Administration issued the "Check Points for Drug Marketing Authorization Holders (Draft for Comment)" (hereinafter referred to as the "Draft for Comment") . Accord
-
Look at three more lines on the eye chart after two weeks!
Time of Update: 2022-05-25
Today, Allergan, a subsidiary of AbbVie, announced that a Phase 3 clinical trial met its primary clinical endpoint: twice-daily use of Vuity eye drops provided sustained relief of presbyopia symptoms .
-
Kelun Pharmaceutical's TROP2 ADC was approved for Phase III clinical trials for triple-negative breast cancer
Time of Update: 2022-05-25
On April 7, Kelun Pharmaceuticals announced that the TROP2 antibody conjugated drug SKB264 (TROP2-ADC) has been approved for clinical treatment of patients with advanced or metastatic triple-negative breast cancer (TNBC) who have failed at least second-line therapy .
-
New study: Finger length can predict the severity of the new crown
Time of Update: 2022-05-25
The results suggest that the finger length ratio and its asymmetry can be used as simple clinical markers of the potential risk of hospitalization due to COVID-19 .
In summary, the study found differences in finger length ratios and their symmetry between patients hospitalized with COVID-19 and controls.
